Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH: Novartis said it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Novartis, which said the deal includes additional payments, royalties, and fees pending the achievement of milestones, already has a blockbuster drug, Cosentyx, in immunology with accelerating sales in psoriasis and ankylosing spondylitis.